EP0141818A1 - Elimination des caracteristiques d'auto-liaison et de transreactivite au staph a d'un anticorps anti-strep - Google Patents

Elimination des caracteristiques d'auto-liaison et de transreactivite au staph a d'un anticorps anti-strep

Info

Publication number
EP0141818A1
EP0141818A1 EP19840900213 EP84900213A EP0141818A1 EP 0141818 A1 EP0141818 A1 EP 0141818A1 EP 19840900213 EP19840900213 EP 19840900213 EP 84900213 A EP84900213 A EP 84900213A EP 0141818 A1 EP0141818 A1 EP 0141818A1
Authority
EP
European Patent Office
Prior art keywords
antibody
acetyl
glucosamine
organism
labelling
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19840900213
Other languages
German (de)
English (en)
Inventor
David H. Katz
Shung-Ho Chang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
QUIDEL
Original Assignee
QUIDEL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by QUIDEL filed Critical QUIDEL
Publication of EP0141818A1 publication Critical patent/EP0141818A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56944—Streptococcus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments

Definitions

  • Streptococcus Group A One of the major antigenic determinants of Streptococcus Group A (Strep-A) is N-acetyl-D-glucosamine. Most Anti-Strep A antibodies bind to the N-acetyl-D- glucosamine determinant. Anti-Strep A also possesses on its own structure N-acetyl-D-glucosamine, however, and will self-bind. This gives a high background which may mask the presence of Strep-A or give a false positive reading for Strep-A immunoglobulins . Moreover, staphylococcal organisms found normally on throat or other body surfaces can bind to the Fc or tail portion of antibodies, including those specific for Strep A, thus giving a false positive reading. We here describe a claim a method for overcoming this serious limitation on assays for Streptococcus Group A.
  • Staphylococcus A is reduced or eliminated.
  • monoclonal Anti- Streptococcal Group A antibody is cleaved to remove the Fc portion which includes an N-acetyl-D-glucosamine moiety.
  • the present invention may be embodied in a kit for carrying out assays in the laboratory, hospital or in the physician's office.
  • the invention may be described as an improved iramunoassay for an organism, using the IgG Anti-organism antibody, the Fc portion of which possesses a moiety to which the IgG Anti-organism antibody can self-bind; the improvement comprising the following steps:
  • step (b) binding Ftab' )-, fragment from step (a) to a solid support to provide thereupon sites for binding antigenic determinant of said organism but which will not cross-bind with the Fc portion of the IgG Anti-organism antibody;
  • step (c) labelling F(ab' )_ fragment from step (a) or IgG organism antibody with a labelling moiety which can be detected;
  • step (d) reacting the products of steps (b)- and (c) with a test medium suspected of containing said organism; and (e) detecting the labelling moiety on the reagent of step (c) as an indication of the presence of said organism in said test medium.
  • the labelling moiety is an enzyme
  • step (a) includes reacting IgG Anti-organism antibody with the antigenic determinant of the antigen for said antibody followed by a cleavage reaction to remove said antigen from said antibody
  • step (b) includes reacting Ftab' ⁇ with antigenic determinant of the antigen for said antibody followed by coupling the resulting F(ab')_- antigen complex to a solid phase support and then by removal of said antigen
  • step (c) includes reacting F(ab') 2 with antigenic determinant of the antigen for said antibody followed by reacting the F(ab ' ) 2 -antigen complex with the labelling reagent.
  • step (b) binding F(ab' )_ fragment from step (a) to a solid support to provide thereupon sites for binding antigenic determinant of Streptococcus Group A but which will not cross-bind with Streptococcus A antigen or Staphylococcus organism;
  • step (c) labelling F( ab' )_ fragment from step (a) or IgG Anti-Streptococcus A antibody with a labelling moiety which can be detected,
  • step (e) detecting the labelling moiety on the reagent of step (c) as an indication of the presence of
  • step (a) includes reacting IgG Anti-Streptococcus Group A antibody with N- acetyl-D-glucosarnine followed by a cleavage reaction to remove the N-acetyl-D-glucosamine containing moiety of said antibody
  • step (b) includes reacting F(ab ' ) 2 with N- acetyl-D-glucosamine followed by coupling the resulting F(ab ' ) _ -N-acetyl-D-glucosamine complex to a solid phase support and then by removal of N-acetyl-D-glucosamine
  • step (c) includes reacting F( ab ' )» with N-acetyl-D- glucosamine followed by reacting the F( ab ' ) -, complex with the label
  • the F(ab') fragment of IgG Anti-Strep Group A is prepared according to the method described by Nisonoff, et al., Arch. Biochem Biophys 89: 230-240 (1960).
  • the IgG at a concentration of 5 mg/ml is dialyzed against 0.054 NaOAc, 0.07M NaCl, pH 4.8.
  • Pepsin is added to give a 3 wt/wt percent concentration and the mixture is incubated at 37 °C for 18 hours.
  • the mixture is subsequently dialyzed against borate- buffered saline (BBS), pH 8.4, and then passed over a N-acetyl-D-glucosamine - Sepharose column and washed with phosphate buffered saline (PBS).
  • BBS borate- buffered saline
  • PBS phosphate buffered saline
  • the F(ab') ⁇ is eluted from the column with PBS containing 0.2M N-acetyl-D-glucosamine.
  • Polystyrene beads (Poly-Sep (trademark) 2% divinyl benzene (DVB), Polysciences, Inc.) are incubated with bovine serum albumin (B ⁇ A), 2 mg/ml in PBS, for 2 hours at room temperature. The beads are washed 3 times with PBS, and then suspended in 2% glutaraldehyde in PBS and mixed for 30 hours at 4°C. The beads are washed 5 times with PBS to remove glutaraldehyde. After the PBS wash, the beads are incubated in PBS solution containing 1 mg/ml anti-Strep A F(ab ' ) ? antibody and 0.1% glutaraldehyde at 4 C overnight. Thereafter, the beads are again washed 5 times with PBS and incubated with IM ethoanolamine, pH 8.0 for 2 hours at 4°C. Finally, the beads are then washed 5 times with PBS.
  • B ⁇ A bovine serum albumin
  • labelled second antibody employs Anti-Strep A or the F(ab * ) fragment thereof labelled with the enzyme ⁇ -galactosidase, although the label per se is not critical and the method is fully suitable for radioimmunoassay or other detection procedures .
  • the present inventive procedure reduced self-binding of Anti-Strep A by a factor of more than ten.
  • Equal volumes of F( a ' ) ⁇ or IgG coupled beads (50 ⁇ l) containing equal number of antibody combining sites were incubated with IgG Anti-Strep A-3-galactosidase conjugate for 20 minutes. The beads were then washed 3 times with PBS-0.2% NP-40. The beads were then incubated in the .substrate for B-galactosidase, o-nitrophenyl- galactopyranoside (ONPG), for 10 minutes.
  • the B-galacto ⁇ sidase produces a yellow color when mixed with its substrate. The color formation may be visually detected or quantitatively determined spectrophotometrically.
  • One of the features of this invention is a particularly advantageous method for preparing F( ab ' ) , Anti-Strep A - polystyrene beads, and for preparing labelled F(ab') 2 Anti-Strep A and for binding an antibody or fragment to a solid phase support, exemplary of which are the polystyrene beads used to exemplify this invention.
  • Polystyrene beads are mixed with BSA, 2.0 mg/ml, in PBS-0.02% NaN, at room temperature for 2 hours, the beads are washed 4 times with PBS and then mixed with PBS containing 2% glutaraldeyhde and 0.02% NaN for 10 hours at room temperature. The beads are then washed 6 times with PBS and mixed in a 1:1 suspension with the affinity purified Anti-Strep Group A antibody in PBS- . 0.02 " i NaN3 with 0. IM N-acetyl-D-glucosamine for 24 hours at 4 °C.
  • Strep Group A carbohydrate is prepared according to the method described by Salton, M.R.J. and Home, R.W. Biochim et
  • kits for diagnostic determinations and for other uses and in research as well, which includes the major reagents and, of course, would typically include vessels, instructions, etc .
  • a kit according to this invention would include labelled F( ab' ) , F(ab' ) 2 - bound to styrene beads or other convenient solid phase support and such vessels, containers and instructions as may be conveniently included. Most conveniently the kit would also contain a developer.
  • B-galactosidase is used as the labelling indicator moiety
  • the principle of the invention involves the combined steps of providing F( ab ' ).,Anti-Strep A, coupling the same to a solid phase support such as polystyrene beads, and also coupling the F(aB' ) 2 Anti-Strep A antibody to a detectable label.
  • a solid phase support such as polystyrene beads
  • F(aB' ) 2 Anti-Strep A antibody to a detectable label.
  • -galactoside is a preferred label, because it gives a very sensitive and pronounced indication and is easily handled.
  • Other labels may, of course, be used.
  • radioimmunoassay (RIA) procedures may be used but present a number of disadvantages, not the least of which is the necessity for handling radioactive reagents and wastes.
  • Other substrates may be used, but polystyrene beads are particularly advantageous being readily available, easily handled, provide a very sensitive assay and bind effectively with antibody.
  • Pepsin cleavage is described, but other cleavage reagents and methods may be used within the concept of the invention.
  • cleavage reagents and methods may be used within the concept of the invention.
  • papain, CNBr, trypsin and other reagents may be used for removing the Fc region or the carbohydrate moiety from the immunoglobuL i n.
  • the sandwich enzyme immunossay is a well-established technique, and the present invention permits the use of this general assay technique in ⁇ very effective, reliable and highJy sensitive assay for Streptococcus Group A.
  • OMPI the F(ab') with an antigenic determinant therefor, e.g., N-acetyl-D-glucosamine, during binding to beads and the same procedure applied to stabilizing the F(ab' ) 2 during labelling with a detectable moiety, e.g., ⁇ -galactosidase, provide an extremely efficient technique and high yield, with improved reliability and higher sensitivity when incorporated into the overall method of this invention.
  • an antigenic determinant therefor e.g., N-acetyl-D-glucosamine
  • This invention finds commercial applicability in the clinical and research assay of Streptococcus Group A as a diagnostic method in the treatment of disease and as a research tool in the development of diagnostic and therapeutic methods and reagents.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Procédé diagnostique et réactifs améliorés pour l'analyse de Streptococcus groupe A, et d'autres organismes contenant des antigènes, dans lequel procédé le fond important résultant de la réaction croisée du groupe A anti-Streptococcique ou de la réaction avec le Staphylococcus est éliminé.
EP19840900213 1983-04-18 1983-11-28 Elimination des caracteristiques d'auto-liaison et de transreactivite au staph a d'un anticorps anti-strep Withdrawn EP0141818A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48606683A 1983-04-18 1983-04-18
US486066 1983-04-18

Publications (1)

Publication Number Publication Date
EP0141818A1 true EP0141818A1 (fr) 1985-05-22

Family

ID=23930466

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19840900213 Withdrawn EP0141818A1 (fr) 1983-04-18 1983-11-28 Elimination des caracteristiques d'auto-liaison et de transreactivite au staph a d'un anticorps anti-strep

Country Status (2)

Country Link
EP (1) EP0141818A1 (fr)
WO (1) WO1984004169A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8618443D0 (en) 1986-07-29 1986-09-03 Univ London Monoclonal antibodies
AUPN214095A0 (en) 1995-04-03 1995-04-27 Australian Water Technologies Pty Ltd Method for detecting microorganisms using flow cytometry
US10168329B2 (en) 2011-08-03 2019-01-01 Quidel Corporation N-acetyl-D-glucosamine for enhanced specificity of Strep A immunoassay
AU2022249139A1 (en) * 2021-04-01 2023-10-05 Becton, Dickinson And Company Methods for enhancing specificity and sensitivity of group a streptococcus immunoassay

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3790447A (en) * 1972-07-05 1974-02-05 Abbott Lab Streptococci diagnostic method
US3896217A (en) * 1973-03-19 1975-07-22 Summa Corp Method and apparatus for radioimmunoassay with regeneration of immunoadsorbent
US4120945A (en) * 1976-07-06 1978-10-17 Becton, Dickinson & Company Substrate coated with receptor and labeled ligand for assays
GB2013688B (en) * 1978-01-26 1982-06-30 Technicon Instr Insolubilised proteins and immunoassays utilising them
US4361647A (en) * 1980-05-22 1982-11-30 Palo Alto Medical Research Foundation Sandwich immunoassay and compositions for use therein
CA1203164A (fr) * 1982-03-09 1986-04-15 Thomas J. Mckearn Conjugats d'anticorps

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8404169A1 *

Also Published As

Publication number Publication date
WO1984004169A1 (fr) 1984-10-25

Similar Documents

Publication Publication Date Title
EP0615129B1 (fr) Procédé pour détecter sélectivement des anticorps périnucléaires cytoplasmiques, anti-neutrophiles de colite ulcéreuse ou de cholangite primaire sclérosante
US5187065A (en) Method and materials for detecting lyme disease
CA1225586A (fr) Methode d'execution d'un dosage immunologique, articles utilises a cette fin et methode de production desdits articles
US5789261A (en) Solid phase immunoassay
CA1256025A (fr) Procede de dosage immuno-chimique d'haptenes et de proteines
EP0124352A2 (fr) Essai protégé de liaison
EP0185722A1 (fr) Anticorps polyclonaux, leur preparation et leur utilisation
JPS61107158A (ja) 検定方法
US4239743A (en) Carrier-bound immunoglobulin fission product and its use in immunologic analyses
US4929543A (en) Process for the determination of an antibody in human body fluids
US5256543A (en) HLA typing
Coombs et al. Assays using red cell-labelled antibodies
US4722890A (en) Quantitative assay for human terminal complement cascade activation
EP0141818A1 (fr) Elimination des caracteristiques d'auto-liaison et de transreactivite au staph a d'un anticorps anti-strep
EP0140896A1 (fr) Protection d'anticorps pendant une modification chimique
CA1146856A (fr) Methode de detection et de dosage des haptenes et des antigenes
JP2821951B2 (ja) 血小板減少症判定
US5061619A (en) Immunoassay using antibody-antigen conjugates
JPH04177166A (ja) ヒトｃ―ペプチドの測定方法
SE467987B (sv) Saett att bestaemma maengden av ett tumoerantigen-immunokomplex
EP0655627B1 (fr) Kit pour une Méthode d'association chimique directe de dimère-D provenant d'un échantillon biologique et permettant le diagnostique et le suivi d'états de thrombolyse et d'hypercoagulabilité
US4820635A (en) Kit for assaying activation of terminal complement cascade
JP3501381B2 (ja) リウマチ因子測定試薬
CA2069546C (fr) Methode diagnostique
Takatori et al. Lewis typing of human bloodstains by enzyme-linked immunosorbent assay (ELISA) using monoclonal anti-Lea and anti-Leb

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19850319

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KATZ, DAVID, H.

Inventor name: CHANG, SHUNG-HO